✦ LIBER ✦

Patterns of Care, Prognosis, and Survival in Patients with Metastatic Gastrointestinal Stromal Tumors (GIST) Refractory to First-Line Imatinib and Second-Line Sunitinib

✍ Scribed by Antoine Italiano; Angela Cioffi; Paola Coco; Robert G. Maki; Patrick Schöffski; Piotr Rutkowski; Axel Le Cesne; Florence Duffaud; Antoine Adenis; Nicolas Isambert; Emmanuelle Bompas; Jean-Yves Blay; Paolo Casali; Mary Louise Keohan; Maud Toulmonde; Cristina R. Antonescu; Maria Debiec-Rychter; Jean-Michel Coindre; Binh Bui

Book ID: 115031646
Publisher: Springer
Year: 2011
Tongue: English
Weight: 384 KB
Volume: 19
Category: Article
ISSN: 1068-9265
DOI: 10.1245/s10434-011-2120-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Treatment Patterns And Costs Of Patients

Treatment Patterns And Costs Of Patients With Gastrointestinal Stromal Tumor (Gist) Receiving First-Line Imatinib

✍ Seal, B.; Green, M.; Stafkey-Mailey, D.; Eaddy, M. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 80 KB

Evaluation of Self-Reported Progression

Evaluation of Self-Reported Progression and Correlation of Imatinib Dose to Survival in Patients with Metastatic Gastrointestinal Stromal Tumors: An Open Cohort Study

✍ Jerry Call; Norman J. Scherzer; P. David Josephy; Christopher Walentas 📂 Article 📅 2009 🏛 Springer US 🌐 English ⚖ 232 KB

212 POSTER A phase II study of the KIT i

212 POSTER A phase II study of the KIT inhibitor XL820 in patients with advanced gastrointestinal stromal tumors (GIST) resistant to or intolerant of imatinib and/or sunitinib

✍ A.J. Wagner; S. Yazji; J.A. Morgan; E. Choy; S. George; M. Hohos; M. O'Mara; G.D 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 59 KB

1919 NEUTROPHIL-TO-LYMPHOCYTE RATIO REDU

1919 NEUTROPHIL-TO-LYMPHOCYTE RATIO REDUCTION AS A SURROGATE MARKER OF PROGNOSIS IN PATIENTS WITH METASTATIC CLEAR CELL RENAL CELL CARCINOMA RECEIVING SUNITINIB AS FIRST-LINE THERAPY

✍ Park, Yong Hyun; Lee, Young Ju; Ku, Ja Hyeon; Kwak, Cheol; Kim, Hyeon Hoe 📂 Article 📅 2013 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 92 KB

4526 POSTER Safety profile of single-age

4526 POSTER Safety profile of single-agent sunitinib malate from the French Temporary Authorization for Use program (Cohort ATU) in metastatic renal cell carcinoma (MRCC) after failure of treatment with cytokines and gastrointestinal stromal tumor (GIST) patients after failure of imatinib mesylate treatment

✍ Oudard, S.; Negrier, S.; Ferrero, J.M.; Gravis, G.; Blay, J.Y.; Le Cesne, A.; Kr 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 58 KB